Rapid and profound shifts in the vaginal microbiota following antibiotic treatment for bacterial vaginosis

Journal of Infectious Diseases

Volumn 212, Issue 5, 2015, Pages 793-802

  Mayer, Bryan T ^a   Srinivasan, Sujatha ^a   Fiedler, Tina L ^a   Marrazzo, Jeanne M ^a   Fredricks, David N ^a   Schiffer, Joshua T ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Bacterial vaginosis; Gardnerella vaginalis; Lactobacillus; Mathematical modeling; Metronidazole; qPCR; Vaginal microbiota

Indexed keywords

METRONIDAZOLE; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL GROWTH; CLINICAL ARTICLE; EVENING DOSAGE; FEMALE; GARDNERELLA VAGINALIS; HUMAN; LACTOBACILLUS; MATHEMATICAL MODEL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SPECIES COMPOSITION; VAGINA FLORA; VAGINITIS; BACTERIUM; BIOTA; DRUG EFFECTS; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; MICROBIOLOGY; THEORETICAL MODEL; TIME; VAGINA; VAGINOSIS, BACTERIAL;

ANTI-BACTERIAL AGENTS; BACTERIA; BIOTA; FEMALE; HUMANS; LONGITUDINAL STUDIES; METRONIDAZOLE; MODELS, THEORETICAL; TIME FACTORS; VAGINA; VAGINOSIS, BACTERIAL;

EID: 84943329147     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv079     Document Type: Article

References (50)

1. Foxman B, Rosenthal M. Implications of the human microbiome project for epidemiology. Am J Epidemiol 2013; 177:197-201.
2. Haiser HJ, Turnbaugh PJ. Is it time for a metagenomic basis of therapeutics? Science 2012; 336:1253-5.
3. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis 2007; 34: 864-9.
4. Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. N Engl J Med 1995; 333:1737-42.
5. Goldenberg RL, Thom E, Moawad AH, Johnson F, Roberts J, Cartis SN. The preterm prediction study: Fetal fibronectin, bacterial vaginosis, and peripartum infection. Obstet Gynecol 1996; 87:656-60.
6. Wiesenfeld HC, Hillier SL, Krohn MA, et al. Lower genital tract infection and endometritis: Insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002; 100:456-63.
7. Ness RB, Kip KE, Hillier SL, et al. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol 2005; 162:585-90.
8. Larsson PG, Platzchristensen JJ, Thejls H, Forsum U, Pahlson C. Incidence of pelvic inflammatory disease after 1st-trimester legal-abortion in women with bacterial vaginosis after treatment with metronidazole-a double-blind, randomized study. Am J Obstet Gynecol 1992; 166: 100-3.
9. Cherpes TL, Melan MA, Kant JA, Cosentino LA, Meyn LA, Hillier SL. Genital tract shedding of herpes simplex virus type 2 in women: effects of hormonal contraception, bacterial vaginosis, and vaginal group B Streptococcus colonization. Clin Infect Dis 2005; 40:1422-8.
10. Wiesenfeld HC, Hillier SL, Krohn MA, Landers DV, Sweet RL. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis 2003; 36:663-8.
11. Watts DH, Fazarri SM, Minkoff H. Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection among HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis 2005; 191:1129-39.
12. Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 1999; 180:1863-8.
13. Taha TE, Hoover DR, Dallabetta GA, et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 1998; 12:1699-706.
14. Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis-2001-2004 National Health and Nutrition Examination Survey data. Obstet Gynecol 2007; 109:114-20.
15. Wang B, Xiao BB, Shang CG, et al. Molecular analysis of the relationship between specific vaginal bacteria and bacterial vaginosis metronidazole therapy failure. Eur J Clin Microbiol Infect Dis 2014; 33:1749-56.
16. Brotman RM, Shardell MD, Gajer P, et al. Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. J Infect Dis 2014; 210:1723-33.
17. Gajer P, Brotman RM, Bai G, et al. Temporal dynamics of the human vaginal microbiota. Sci Transl Med 2012; 4:132ra52.
18. Santiago GL, Cools P, Verstraelen H, et al. Longitudinal study of the dynamics of vaginal microflora during two consecutive menstrual cycles. PLoS One 2011; 6:e28180.
19. Srinivasan S, Liu C, Mitchell CM, et al. Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. PLoS One 2010; 5:e10197.
20. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-6.
21. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-91.
22. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-6.
23. Ramratnam B, Bonhoeffer S, Binley J, et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999; 354:1782-5.
24. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010; 2:30ra2.
25. Schiffer JT. Mucosal HSV-2 specific CD8+ T-Cells represent containment of prior viral shedding rather than a correlate of future protection. Front Immunol 2013; 4:209.
26. Schiffer JT, Swan D, Corey L, Wald A. Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus-2 directed antiviral agents. Antimicrob Agents Chemother 2013; 57:5820-9.
27. Amsel R, Totten PA, Spiegel CA, Chen KCS, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983; 74:14-22.
28. Centers for Disease Control and Prevention; Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55:1-94.
29. Fredricks DN, Fiedler TL, Thomas KK, Mitchell CM, Marrazzo JM. Changes in vaginal bacterial concentrations with intravaginal metronidazole therapy for bacterial vaginosis as assessed by quantitative PCR. J Clin Microbiol 2009; 47:721-6.
30. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991; 29:297-301.
31. Antonopoulos DA, Huse SM, Morrison HG, Schmidt TM, Sogin ML, Young VB. Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect Immun 2009; 77:2367-75.
32. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008; 6:e280.
33. Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One 2010; 5:e9836.
34. Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006; 193:1478-86.
35. Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol 2005; 106:1013-23.
36. Swidsinski A, Mendling W, Loening-Baucke V, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol 2008; 198: 97.e1-6.
37. Verstraelen H, Swidsinski A. The biofilm in bacterial vaginosis: implications for epidemiology, diagnosis and treatment. Curr Opin Infect Dis 2013; 26:86-9.
38. Aguin T, Akins RA, Sobel JD. High-dose vaginal maintenance metronidazole for recurrent bacterial vaginosis: a pilot study. Sex Transm Dis 2014; 41:290-1.
39. Edwards DI. Nitroimidazole drugs-action and resistance mechanisms. II. Mechanisms of resistance. J Antimicrob Chemother 1993; 31:201-10.
40. Easmon CS, Ison CA, Kaye CM, Timewell RM, Dawson SG. Pharmacokinetics of metronidazole and its principal metabolites and their activity against Gardnerella vaginalis. Br J Vener Dis 1982; 58:246-9.
41. Srinivasan S, Hoffman NG, Morgan MT, et al. Bacterial Communities in Women with Bacterial Vaginosis: High Resolution Phylogenetic Analyses Reveal Relationships of Microbiota to Clinical Criteria. PLoS One 2012; 7:e37818.
42. Danielsson D, Teigen PK, Moi H. The genital econiche: focus on microbiota and bacterial vaginosis. Ann N Y Acad Sci 2011; 1230:48-58.
43. Zozaya-Hinchliffe M, Lillis R, Martin DH, Ferris MJ. Quantitative PCR assessments of bacterial species in women with and without bacterial vaginosis. J Clin Microbiol 2010; 48:1812-9.
44. Ferris MJ, Norori J, Zozaya-Hinchliffe M, Martin DH. Cultivationindependent analysis of changes in bacterial vaginosis flora following metronidazole treatment. J Clin Microbiol 2007; 45:1016-8.
45. Martin DH, Zozaya M, Lillis R, Miller J, Ferris MJ. The microbiota of the human genitourinary tract: trying to see the forest through the trees. Trans Am Clin Climatol Assoc 2012; 123:242-56.
46. Verstraelen H, Verhelst R, Claeys G, De Backer E, Temmerman M, Vaneechoutte M. Longitudinal analysis of the vaginal microflora in pregnancy suggests that L. crispatus promotes the stability of the normal vaginal microflora and that L. gasseri and/or L. iners are more conducive to the occurrence of abnormal vaginal microflora. BMC Microbiol 2009; 9:116.
47. Ma B, Forney LJ, Ravel J. Vaginal microbiome: rethinking health and disease. Annu Rev Microbiol 2012; 66:371-89.
48. Ling Z, Kong J, Liu F, et al. Molecular analysis of the diversity of vaginal microbiota associated with bacterial vaginosis. BMC Genomics 2010; 11:488.
49. Stratton CW, Weeks LS, Aldridge KE. Comparison of the bactericidal activity of clindamycin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group. Diagn Microbiol Infect Dis 1991; 14:377-82.
50. Stratton CW, Weeks LS, Aldridge KE. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group. Diagn Microbiol Infect Dis 1992; 15:321-30.